Correlation between the extent of coronary atherosclerosis and lipid profile

Molecular and Cellular Biochemistry

Volumn 246, Issue 1-2, 2003, Pages 25-30

  Tarchalski, Janusz ^a   Guzik, Przemysław ^b   Wysocki, Henryk ^b  

^a Department of Cardiology   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cholesterol; Coronary artery atherosclerosis; Gensini Score; HDL; LDL; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; CHOLESTEROL ESTERASE; GLYCEROL KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXIDASE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIET RESTRICTION; ENZYME ASSAY; FEMALE; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCORING SYSTEM;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; TRIGLYCERIDES;

ANGINA;

EID: 0038417529     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023443609730     Document Type: Review

References (46)

1. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85: 2025-2033, 1992
2. Stein JH, Rosenson RS: Lipoprotein Lp(a) excess and coronary heart disease Arch Intern Med 157: 1170-1176, 1997
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
4. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML: The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: A joint statement by the American Heart Association and the National, Heart, Lung, and Blood Institute. Circulation 81: 1721-1733, 1990
5. Grundy SM, Goodman DS, Rifkind BM, Cleeman JI: The place of HDL in cholesterol management. A perspective from the National Cholesterol Education Program. Arch Intern Med 149: 505-510, 1989
6. Rosenson RS: Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 156: 1278-1284, 1996
7. Kinosian B, Glick H, Garland G: Cholesterol and coronary heart disease: Predicting risks by levels and ratios. Ann Intern Med 121: 641-647, 1994
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009, 1996
10. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF Rubins HB: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA 285: 1585-1591, 2001
11. Avins AL, Neuhaus, JM: Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 160: 1937-1944, 2000
12. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81: 7B-12B, 1998
13. Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH, Haffner SM: Hyperlipidemia: Diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 85: 2089-2112, 2000
14. Marwick T, D'Hondt A-M, Baudhuin T, Willemart B, Wijns W, Detry J-M: Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: Combination with echocardiography or Scintigraphy, or both? J Am Coll Cardiol 22: 159-167, 1993
15. Hoffmeister A, Rothenbacher D, Bazner U, Frohlich M, Brenner H, Hombach V, Koenig W: Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 87: 262-266,2001
16. Romm PA, Green CE, Reagan K, Rackley CE: Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am J Cardiol 67: 479-83, 1991
17. Lekakis JP, Papamichael CM, Cimponeriu AT, Stamatelopoulos KS, Papaioannou TG, Kanakakis J, Alevizaki MK, Papapanagiotou A, Kalofoutis AT, Stamatelopoulos SF: Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol 85: 949-952, 2000
18. Cerne D, Kaplan-Pavlovcic S, Kranjec I, Jurgens G: Mildly elevated serum creatinine concentration correlates with the extent of coronary atherosclerosis. Ren Fail 22: 799-808, 2000
19. Brown MS, Goldstein JL:A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47, 1986
20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915 - 924, 1989
21. Hiltunen TP, Luoma JS, Nikkari T, Yla-Herttuala S: Expression of LDL receptor, VLDL receptor, LDL receptor-related protien, and scavenger receptor in rabbit atherosclerotic lesions. Marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 97: 1079-1086, 1998
22. Klouche M, Rose-John S, Schmiedt W, Bhakdi S: Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 101: 1799-1805, 2000
23. Dimmeler S, Haendeler J, Galle J, Zeiher AM: Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. Circulation 95: 1760-1763, 1997
24. Li D, Mehta JL: Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101: 2889-2895, 2000
25. Mathew V, Cannan CR, Miller VM, Barber DA, Hasdai D, Schwartz RS, Holmes DR Jr, Lerman A: Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 96: 1930-1936, 1997
26. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P: Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93: 1647-1650, 1996
27. Rosenson RS, Lowe GD: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 140: 271-80, 1998
28. Chen LY, Mehta P, Mehta JL: Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: Relevance of the effect of oxidized LDL on platelet function. Circulation 93: 1740-1746, 1996
29. Ross R: The pathogenesis of atherosclerosis. A perspective for the 1990s. Nature 362: 801-809, 1993
30. Tall AR: Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 86: 379-384, 1990
31. Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubster O, Ouellette BF, Sensen CW, Fichter K, Mott S, Dennis M, Boucher B, Pimstone S, Genest J Jr, Kastelein JJ, Hayden MR: Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354: 1341-1346, 1999
32. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M: Human serum paraoxonases (PON1)Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510-2517, 2000
33. James RW, Leviev I, Righetti A: Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101: 2252-2257, 2000
34. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287, 1998
35. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE: Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 68: 1425-1430, 1991
36. Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM: HDL and apolipoprotein A-1 protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 14: 1775-1783, 1994
37. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA: High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103: 219-227, 1999
38. Rosenson RS: Approach to the patient with hypertriglyceridemia-I. In: B.D. Rose(ed).UpToDate 2001; Version 9.3. UpToDate Inc., Wellesley, MA, USA, http://www.uptodate.com
39. Garber AM, Avins AL: Triglyceride concentration and coronary heart disease. Not yet proved of value as a screening test. BMJ 309: 2-3, 1994
40. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF: Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 103: 1191-1199, 1999
41. Rosenson RS, Shott S, Lu L, Tangney CC: Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med 110: 488-492, 2001
42. Reaven GM: Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 44: 121-131, 1993
43. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E: Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 12: 19-27, 1992
44. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow EF: Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 14: 438-442, 1994
45. Oishi Y, Wakatsuki T, Nishikado A, Oki T, Ito S: Circulating adhesion molecules and severity of coronary artherosclerosis. Coron Artery Dis 11: 77-81, 2000
46. Inoue T, Matsunaga R, Morooka S, Uehara Y: Serum N-acetyl-beta-D-gulucosaminidase activity increases in association with insulin resistance in patients with coronary artery disease. Atherosclerosis 149: 117-122, 2000